STOCK TITAN

Rani Therapeutics Holdings Inc - RANI STOCK NEWS

Welcome to our dedicated news page for Rani Therapeutics Holdings (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rani Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rani Therapeutics Holdings's position in the market.

Rhea-AI Summary
Rani Therapeutics reported positive topline results from Phase 1 study of RT-111, an oral anti-Interleukin 12/23 antibody, and preclinical data on GLP-1 Incretin Triagonist. Cash runway extended to 2025. Financial results show a decrease in cash and an increase in R&D and G&A expenses. Key milestones include RaniPill HC Phase 1 trials and Phase 2 trial of RT-102 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Summary
Rani Therapeutics Holdings, Inc. (RANI) announces the release of financial results for Q4 and full year 2023, along with a business update. The conference call and webcast are scheduled for March 20, 2024, at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
-
Rhea-AI Summary
Rani Therapeutics Holdings, Inc. announced positive topline results from its Phase 1 clinical study of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar, CT-P43. The study showed that RT-111 was well-tolerated and delivered ustekinumab with high bioavailability. The Phase 1 study demonstrated that oral RT-111 delivered ustekinumab biosimilar in a dose proportional manner and with high bioavailability (estimated at 84% relative to subcutaneous injection). RT-111 also demonstrated a higher Cmax and shorter Tmax compared to ustekinumab delivered by subcutaneous injection. The conference call to discuss the results from the Phase 1 clinical trial of RT-111 will be held on February 5, 2024, at 8:30 a.m. ET / 5:30 a.m. PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
Rhea-AI Summary
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company (Nasdaq: RANI), announced preclinical data supporting the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments. The data highlighted that transenteric delivery mimicking the RaniPill’s route of drug administration results in pharmacodynamics comparable to subcutaneous injection for an incretin triagonist. The recent study of an incretin triagonist showed weight loss and reduction in serum lipids comparable to that observed via the subcutaneous injection route. RaniPill has the potential to create oral alternatives for single and multiagonist drugs with differentiated dosing flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Summary
RANI - Rani Therapeutics extends cash runway to 2025, prioritizes strategic programs, and reports clinical trial updates. Initiates Phase 1 trial of RT-111 and expects Phase 2 trial of RT-102 by 2023 end. RaniPill HC shows promising drug delivery in preclinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
-
Rhea-AI Summary
Rani Therapeutics announces strategic prioritization of programs, expansion of manufacturing, and cost reduction initiatives. Cash runway extended into 2025. RT-101 program discontinued, workforce reduced by 25%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
Rhea-AI Summary
Rani Therapeutics announces preclinical data supporting the safety and tolerability of RaniPill® drug delivery platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary
Rani Therapeutics announces successful oral delivery of Humira® via RaniPill® HC in preclinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary
Rani Therapeutics to present abstract on RT-102 at ASBMR 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
conferences
Rhea-AI Summary
Rani Therapeutics initiates Phase 1 trial for RT-111, an oral ustekinumab biosimilar. Topline results expected in early Q1 2024. Ustekinumab sales were $6.4B in the US and $9.7B worldwide in 2022. RT-111 aims to provide a convenient oral alternative to injections for autoimmune diseases. Celltrion has a right of first negotiation for RT-111.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rani Therapeutics Holdings Inc

Nasdaq:RANI

RANI Rankings

RANI Stock Data

278.11M
13.44M
48.42%
13.37%
7.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Jose

About RANI

Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.